NRAS and cancer: The top four mutated genes in pediatric cancers were NRAS (1.8%), KRAS (0.9%), JAK2 (0.3%), and CREBBP (0.3%), highlighting that these genes should be analyzed further to assess the clinical significance of these mutations (Figure 3).